Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions

Orally administered levodopa remains the most effective symptomatic treatment for Parkinson's disease (PD). The introduction of levodopa therapy is often delayed, however, because of the fear that it might be toxic for the remaining dopaminergic neurons and, thus, accelerate the deterioration of patients. However, in vivo evidence of levodopa toxicity is scarce. We have evaluated the effects of a 6‐month oral levodoapa treatment on several dopaminergic markers, in rats with moderate or severe 6‐hydroxydopamine‐induced lesions of mesencephalic dopamine neurons and sham‐lesioned animals. Counts of tyrosine hydroxylase (TH)‐immunoreactive neurons in the substantia nigra and ventral tegmental area showed no significant difference between levodopa‐treated and vehicle‐treated rats. In addition, for rats of the sham‐lesioned and severely lesioned groups, immunoradiolabeling for TH, the dopamine transporter (DAT), and the vesicular monoamine transporter (VMAT2) at the striatal level was not significantly defferent between rats treated with levodopa or vehicle. It was unexpected that quantification of immunoautoradiograms showed a partial recovery of all three dopaminergic markers (TH, DAT, and VMAT2) in the denervated territories of the striatum of moderately lesioned rats receiving levodopa. Furthermore, the density of TH‐positive fibers observed in moderately lesioned rats was higher in those treated chronically with levodopa than in those receiving vehicle. Last, that chronic levodopa administration reversed the up‐regulation of D2 dopamine receptors seen in severely lesioned rats provided evidence that levodopa reached a biologically active concentration at the basal ganglia. Our results demonstrate that a pharmacologically effective 6‐month oral levodopa treatment is not toxic for remaining dopamine neurons in a rat model of PD but instead promotes the recovery of striatal innervation in rats with partial lesions.

[1]  R. Wurtman,et al.  Long‐term administration of L‐DOPA does not damage dopaminergic neurons in the mouse , 1981, Neurology.

[2]  J. Thibault,et al.  Dopamine increases the expression of tyrosine hydroxylase and aromatic amino acid decarboxylase in primary cultures of fetal neurons. , 1991, Brain research. Developmental brain research.

[3]  J. Langston,et al.  Oxidation reactions in Parkinson's disease. Discussion , 1990 .

[4]  E. Abercrombie,et al.  Neurochemical Responses to 6‐Hydroxydopamine and L‐Dopa Therapy: Implications for Parkinson's Disease a , 1992, Annals of the New York Academy of Sciences.

[5]  Mitsutoshi Yamamoto,et al.  Differential effects of chronic l-DOPA treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine , 1994, Neuroscience Letters.

[6]  D. Graham,et al.  Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. , 1978, Molecular pharmacology.

[7]  F. Hefti,et al.  Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture , 1990, Journal of neuroscience research.

[8]  S. Fahn,et al.  Considerations in the management of parkinsonism , 1978, Neurology.

[9]  R. Clavier,et al.  Nigrostriatal Dopaminergic Neurons Remain Undamaged in Rats Given High Doses of l‐DOPA and Carbidopa Chronically , 1984, Journal of neurochemistry.

[10]  C. Goetz Dopaminergic agonists in the treatment of Parkinson's disease , 1990, Neurologic clinics.

[11]  Y. Agid,et al.  Does levodopa aggravate Parkinson's disease? , 1988, Neurology.

[12]  R. Edwards,et al.  Differential expression of two vesicular monoamine transporters , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[13]  M. Mena,et al.  Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid , 1993, Neuroreport.

[14]  L. Grégoire,et al.  Risk Factors for Peak Dose Dyskinesia in 100 Levodopa-treated Parkinsonian Patients , 1996, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[15]  S. Miller,et al.  Prolongation of the life-span in mice adapted to large amounts of L-dopa. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[16]  C. Clarke Does levodopa therapy delay death in Parkinson's disease? A review of the evidence , 1995, Movement disorders : official journal of the Movement Disorder Society.

[17]  Anthony E. Lang,et al.  Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa , 1996 .

[18]  R P Lesser,et al.  Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapy , 1979, Neurology.

[19]  E. Hirsch,et al.  Cellular Quantification of Tyrosine Hydroxylase in the Rat Brain by Immunoautoradiography , 1993, Journal of neurochemistry.

[20]  Y. Agid,et al.  Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. , 1973, Nature: New biology.

[21]  E. Abercrombie,et al.  Effects ofl-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats , 1990, Brain Research.

[22]  D. Dexter,et al.  Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease. , 1996, Free radical research.

[23]  J. M. Ree,et al.  Reinnervation after destruction of the dopaminergic system in the rat nucleus accumbens: a quantitative immunohistochemical analysis , 1996, Neuroscience Letters.

[24]  Y Agid,et al.  Mitochondrial Free Radical Signal in Ceramide‐Dependent Apoptosis: A Putative Mechanism for Neuronal Death in Parkinson's Disease , 1997, Journal of neurochemistry.

[25]  L. Naudon,et al.  Reserpine Affects Differentially the Density of the Vesicular Monoamine Transporter and Dihydrotetrabenazine Binding Sites , 1996, The European journal of neuroscience.

[26]  Y. Agid,et al.  Absence of neurotoxicity of chronic L‐DOPA in 6‐hydroxydopaminelesioned rats , 1997, Neuroreport.

[27]  M. Yahr,et al.  Autopsy findings in parkinsonism following treatment with levodopa , 1972, Neurology.

[28]  Hoehn Mm,et al.  Parkinson's disease: progression and mortality. , 1987 .

[29]  J. Bennett,et al.  L-dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity? , 1994, Neuroreport.

[30]  Y. Agid,et al.  Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra , 1996, Brain Research.

[31]  C. Marsden,et al.  L‐Dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain , 1995, Movement disorders : official journal of the Movement Disorder Society.

[32]  D. Maraganore,et al.  Levodopa therapy and survival in idiopathic Parkinson's disease , 1993, Neurology.

[33]  D. Graham Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. , 1978, Molecular pharmacology.

[34]  Steven Moran,et al.  Sprouting of dopaminergic fibers from spared mesencephalic dopamine neurons in the unilateral partial lesioned rat , 1995, Brain Research.

[35]  R. Burke,et al.  6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[36]  J. G. Nutt,et al.  Long-duration response to levodopa , 1995, Neurology.

[37]  E. Melamed Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease. , 1986, Archives of neurology.

[38]  J. Kurtzke,et al.  Death rates from Parkinson's disease in Norway reflect increased survival , 1991, Neurology.

[39]  J. Siegfried,et al.  Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor. , 1976, European neurology.

[40]  S. Fahn,et al.  Selegiline and mortality in Parkinson's disease , 1996, Annals of neurology.

[41]  C. Mytilineou,et al.  Toxic and Protective Effects of l‐DOPA on Mesencephalic Cell Cultures , 1993, Journal of neurochemistry.

[42]  C. Waters,et al.  Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. , 1995, The Journal of clinical investigation.

[43]  M. Muenter,et al.  Multi‐center study of Parkinson mortality with early versus later dopa treatment , 1987, Annals of neurology.

[44]  A. Björklund,et al.  Brain-derived neurotrophic factor and neurotrophin- 4 5 modify neurotransmitter-related gene expression in the 6-hydroxydopamine-lesioned rat striatum , 1995, Neuroscience.

[45]  A. Rajput,et al.  Chronic low‐dose levodopa therapy in Parkinson's disease , 1984, Neurology.

[46]  C. Marsden,et al.  The effect ofl-DOPA and carbidopa treatment on the survival of rat fetal dopamine grafts assessed by tyrosine hydroxylase immunohistochemistry and [3H]mazindol autoradiography , 1991, Neuroscience.

[47]  C. Gall,et al.  Expression of Neurotrophins by Midbrain Dopaminergic Neurons , 1993, Experimental Neurology.

[48]  P. Ballard,et al.  Parkinsonism Induced By 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine (MPTP): Implications for Treatment and the Pathogenesis of Parkinson’s Disease , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[49]  A. Nieoullon,et al.  Differential regional effects of long-term L-DOPA treatment on preproenkephalin and preprotachykinin gene expression in the striatum of 6-hydroxydopamine-lesioned rat. , 1997, Brain research. Molecular brain research.

[50]  I. Kanazawa,et al.  Dopaminergic stimulation up‐regulates the in vivo expression of brain‐derived neurotrophic factor (BDNF) in the striatum , 1992, FEBS letters.

[51]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[52]  J. Townsend,et al.  Pre- and Postsynaptic Neurotoxic Effects of Dopamine Demonstrated by Intrastriatal Injection , 1993, Experimental Neurology.

[53]  E. Mufson,et al.  Striatal Extracts from Patients with Parkinson's Disease Promote Dopamine Neuron Growth in Mesencephalic Cultures , 1993, Experimental Neurology.

[54]  M. Yahr LONG-TERM LEVODOPA IN PARKINSON'S DISEASE , 1977, The Lancet.

[55]  B. McEwen,et al.  Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra , 1994, Brain Research.

[56]  F. Mcdowell,et al.  Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients. , 1975, Annals of internal medicine.

[57]  P. Jenner,et al.  Suppressive effect of L‐dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6‐hydroxydopamine , 1993, Movement disorders : official journal of the Movement Disorder Society.

[58]  S. Fahn,et al.  Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity , 1993, Annals of neurology.

[59]  J. Schneider Levodopa-induced dyskinesias in parkinsonian monkeys: Relationship to extent of nigrostriatal damage , 1989, Pharmacology Biochemistry and Behavior.

[60]  S. Fahn Is levodopa toxic? , 1996, Neurology.

[61]  F. Colpaert,et al.  Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: A possible role for the locus coeruleus in the progression of Parkinson's disease , 1991, Neuroscience.

[62]  Protective effect of carbidopa on hydroxyl radical generation in the rat striatum by dopamine , 1996, Neuroscience Letters.

[63]  Y. Naum,et al.  Growth of Pulmonary Alveolar Macrophages in vitro , 1973, Nature.

[64]  S. Hirai,et al.  Dopa and dopamine cause cultured neuronal death in the presence of iron , 1991, Journal of the Neurological Sciences.

[65]  S. K. Han,et al.  l‐DOPA Up‐Regulates Glutathione and Protects Mesencephalic Cultures Against Oxidative Stress , 1996, Journal of neurochemistry.

[66]  S. Fahn,et al.  Neurotoxicity of levodopa on catecholamine‐rich neurons , 1992, Movement disorders : official journal of the Movement Disorder Society.

[67]  C. Joseph,et al.  Levodopa in Parkinson disease: A long‐term appraisal of mortality , 1978, Annals of neurology.

[68]  P. Rosenberg,et al.  TOPA quinone, a kainate-like agonist and excitotoxin is generated by a catecholaminergic cell line , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[69]  C. Goetz,et al.  Levodopa reduces the growth promoting effects of striatal extracts on rostral mesencephalic tegmentum cultures , 1991, Experimental Neurology.

[70]  J. Olney,et al.  Excitotoxicity of l-DOPA and 6-OH-DOPA: Implications for Parkinson's and Huntington's diseases , 1990, Experimental Neurology.

[71]  M. Zigmond,et al.  Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[72]  S. Fahn,et al.  The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.

[73]  C. Sladek,et al.  Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons , 1990, Experimental Neurology.

[74]  N. Quinn,et al.  Preservation of the substanitia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four‐year period , 1986, Movement disorders : official journal of the Movement Disorder Society.

[75]  M. Musicco,et al.  The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa , 1991, Neurology.

[76]  R. Wurtman,et al.  Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization , 1980, Brain Research.

[77]  M. Martres,et al.  A detailed mapping of dopamine D-2 receptors in rat central nervous system by autoradiography with [125I]iodosulpride , 1987, Neuroscience.

[78]  E. van der Velde,et al.  Response fluctuations in Parkinson's disease , 1990, Neurology.

[79]  D. Calne The free radical hypothesis in idiopathic parkinsonism: Evidence against it , 1992, Annals of neurology.

[80]  F. Mcdowell,et al.  “Early” initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease , 1991, Neurology.

[81]  J. Meerwaldt,et al.  Factors that influence the occurrence of response variations in Parkinson's disease , 1987, Annals of neurology.

[82]  M. Mena,et al.  l‐DOPA Inhibits Complex IV of the Electron Transport Chain in Catecholamine‐Rich Human Neuroblastoma NB69 Cells , 1995, Journal of neurochemistry.

[83]  J. Thibault,et al.  Quantitative Autoradiography of Tyrosine Hydroxylase Immunoreactivity in the Rat Brain , 1991, Journal of neurochemistry.

[84]  W. H. Oertel,et al.  Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat , 1994, Neuroscience.

[85]  Anthony E. Lang,et al.  Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.

[86]  Y. Agid,et al.  Long‐Term Induction of Tyrosine Hydroxylase Expression: Compensatory Response to Partial Degeneration of the Dopaminergic Nigrostriatal System in the Rat Brain , 1995, Journal of neurochemistry.